- Home
- RNST vs TNGX Comparison
RNST vs TNGX Comparison
Compare RNST & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNST | TNGX |
|---|---|---|
| Founded | 1904 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNST | TNGX |
|---|---|---|
| Price | $38.88 | $23.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $47.71 | $45.18 |
| AVG Volume (30 Days) | 649.5K | ★ 2.9M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $12.20 | N/A |
| Revenue Next Year | $3.25 | N/A |
| P/E Ratio | $20.90 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $33.04 | $6.69 |
| 52 Week High | $44.54 | $34.39 |
Technical Indicators
Market Signals| Indicator | RNST | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 48.85 |
| Support Level | $35.04 | $19.74 |
| Resistance Level | $40.84 | $25.93 |
| Average True Range (ATR) | 0.67 | 1.58 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 28.09 | 51.64 |
Price Performance
Historical ComparisonAbout RNST Renasant Corporation
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.